Author:
Vittet D,Rondot A,Cantau B,Launay J M,Chevillard C
Abstract
The binding of 3H-labelled [8-arginine]vasopressin to human platelets or crude platelet membranes was examined. Both preparations specifically bound [8-arginine]vasopressin. The binding increased linearly with protein concentration, it was temperature- and time-dependent, saturable and could be reversed to a large extent by EDTA (10 mM). In this latter case, addition of an excess of MgCl2 (20 mM) restored the initial level of binding. Intact platelets and membranes derived from these platelets presented a single population of binding sites with a dissociation constant (Kd) of 1.3 +/- 0.2 and 1.8 +/- 0.3 nM and a maximal binding capacity of 142 +/- 48 and 270 +/- 17 fmol/mg of protein, respectively. The Kd values of various analogues correlated well with those determined on rat liver membrane V1 vasopressin receptors but not with those determined on rat kidney membrane V2 receptors.
Subject
Cell Biology,Molecular Biology,Biochemistry
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Synergistic interaction of endogenous platelet-activating factor and vasopressin in generating angina in rats;European Journal of Pharmacology;2004-09
2. Synthesis and Structure−Activity Relationships of 5,6,7,8-Tetrahydro-4H-thieno[3,2-b]azepine Derivatives: Novel Arginine Vasopressin Antagonists;Journal of Medicinal Chemistry;2003-11-27
3. Safety, Tolerability, and Pharmacokinetics of SR 49059, a V1A Vasopressin Receptor Antagonist, After Repeated Oral Administration in Healthy Volunteers;Advances in Experimental Medicine and Biology;1998
4. Vasopressin Receptors;Advances in Experimental Medicine and Biology;1998
5. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs;European Journal of Pharmacology;1997-02